ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
To determine efficacy in the delivery of chronomodulated chemotherapy.
应用场景：
创建时间：
2006-10-15
相关数据集
AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients
The aim of this study is to evaluate the efficacy of mFOLFOXIRI plus cetuximab and avelumab as first line treatment of patients with initially unresectable and previously untreated RAS wild-type metas
NIAID Data Ecosystem90
Genistein in Treatment of Metastatic Colorectal Cancer
Colorectal neoplasms are the third most common malignancies in the United States. Patients with metastatic (stage IV) colorectal cancer have a median life expectancy of 2 years. The response rates to
NIAID Data Ecosystem60
The application and exploration of Fruquintnib combined with TAS-102 and Stereotactic Body Radiotherapy(SBRT)for Third-line and Beyond Treatment of Metastatic Colorectal Cancer
Interventions: Cohort 1:Fruquintnib combined with TAS-102 and SBRT;Cohort 2:Fruquintnib combined with TAS-102 Primary outcome(s): Progression-free survival assessed by the investigator Study Design: F
NIAID Data Ecosystem50
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI. The randomized,
NIAID Data Ecosystem60
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance
This is a hypothesis driven, open label, single-arm, multiple centers, Phase II trial. The trial has been designed to prove or disprove whether a rechallenge with panitumumab can achieve an objective
NIAID Data Ecosystem50
